By Product-
By Service-
By End-Users-
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Rest of Middle East and Africa
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Investigational New Drug CDMO Market Snapshot
Chapter 4. Global Investigational New Drug CDMO Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Product Type Estimates & Trend Analysis
5.1. by Product Type & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Product Type:
5.2.1. Percutaneous Endovascular Aneurysm Repair (EVAR)
5.2.2. Fenestrated EVAR
5.2.3. Aortic Stents Biodegradable Stents
5.2.4. Self- Expanding Nitinol Stents
5.2.5. Thoracic Aortic Aneurysm Grafts
5.2.6. Other Devices
Chapter 6. Market Segmentation 2: by Service Estimates & Trend Analysis
6.1. by Service & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Service:
6.2.1. Contract Development
6.2.1.1. Small Molecule
6.2.1.1.1. Bioanalysis and DMPK studies
6.2.1.1.2. Toxicology Testing
6.2.1.1.3. Pathology and safety pharmacology studies
6.2.1.1.4. Drug substance synthetic route development
6.2.1.1.5. Drug substance process development
6.2.1.1.6. Form selection crystallization process development
6.2.1.1.7. Scale-up of drug substance
6.2.1.1.8. Preformulation
6.2.1.1.9. Preclinical formulation selection
6.2.1.1.10. First in Man Formulation/Process Development
6.2.1.1.11. Analytical method development/validation
6.2.1.1.12. Release testing of drug substance and drug product
6.2.1.1.13. Work up Purification Steps
6.2.1.1.14. Telescoping & Process Refining
6.2.1.1.15. Initial Optimization
6.2.1.1.16. Formal stability of drug substance and drug product
6.2.1.2. Large Molecule
6.2.1.2.1. Cell Line development
6.2.1.2.2. Process Development
6.2.1.2.2.1. Upstream
6.2.1.2.2.1.1. Microbial
6.2.1.2.2.1.2. Mammalian
6.2.1.2.2.1.3. Others
6.2.1.2.2.2. Downstream
6.2.1.2.2.2.1. MABs
6.2.1.2.2.2.2. Recombinant proteins
6.2.1.2.2.2.3. Others
6.2.2. Contract Manufacturing
6.2.2.1. Small Molecule
6.2.2.1.1. Oral Solids
6.2.2.1.2. Liquid and Semi-solids
6.2.2.1.3. Injectables
6.2.2.1.4. Others
6.2.2.2. Large Molecule
6.2.2.2.1. MABs
6.2.2.2.2. Recombinant proteins
6.2.2.2.3. Others
Chapter 7. Market Segmentation 3: by End-user Estimates & Trend Analysis
7.1. by End-user & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End-user:
7.2.1. Pharmaceutical Companies
7.2.2. Biotech Companies
7.2.3. Others (Government, Research Institutes, Academic Institutes, Etc.)
Chapter 8. Investigational New Drug CDMO Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Investigational New Drug CDMO Market Revenue (US$ Million) Estimates and Forecasts by Product Type, 2021-2034
8.1.2. North America Investigational New Drug CDMO Market Revenue (US$ Million) Estimates and Forecasts by Service, 2021-2034
8.1.3. North America Investigational New Drug CDMO Market revenue (US$ Million) by End-user, 2021-2034
8.1.4. North America Investigational New Drug CDMO Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Investigational New Drug CDMO Market revenue (US$ Million) by Product Type, 2021-2034
8.2.2. Europe Investigational New Drug CDMO Market revenue (US$ Million) by Service, 2021-2034
8.2.3. Europe Investigational New Drug CDMO Market revenue (US$ Million) by End-user, 2021-2034
8.2.4. Europe Investigational New Drug CDMO Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Investigational New Drug CDMO Market revenue (US$ Million) by Product Type, 2021-2034
8.3.2. Asia Pacific Investigational New Drug CDMO Market revenue (US$ Million) by Service, 2021-2034
8.3.3. Asia-Pacific Investigational New Drug CDMO Market revenue (US$ Million) by End-user, 2021-2034
8.3.4. Asia Pacific Investigational New Drug CDMO Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Investigational New Drug CDMO Market revenue (US$ Million) by Product Type, 2021-2034
8.4.2. Latin America Investigational New Drug CDMO Market revenue (US$ Million) by Service, 2021-2034
8.4.3. Latin America Investigational New Drug CDMO Market revenue (US$ Million) by End-user, 2021-2034
8.4.4. Latin America Investigational New Drug CDMO Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Investigational New Drug CDMO Market revenue (US$ Million) by Product Type, 2021-2034
8.5.2. Middle East & Africa Investigational New Drug CDMO Market revenue (US$ Million) by Service, 2021-2034
8.5.3. Middle East & Africa Investigational New Drug CDMO Market revenue (US$ Million) by End-user, 2021-2034
8.5.4. Middle East & Africa Investigational New Drug CDMO Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Covance Inc.
9.2.2. Charles River Laboratories Inc.
9.2.3. Cambrex Corporation
9.2.4. IQVIA Holdings Inc.
9.2.5. Syneos Health
9.2.6. Lonza
9.2.7. Catalent
9.2.8. Recipharm AB
9.2.9. Siegfried Holding AG
9.2.10. Thermo Fisher Scientific Inc.
9.2.11. Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.